AIM ImmunoTech Inc. — Director's Dealing 2018

Apr 19, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2018-04-12

Reporting Person: EQUELS THOMAS K. (Director, Exec. Vice Chairman/CEO/Pres.)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-04-12	Options to buy Common Stock	$0.38	A	125000	Acquired	2028-04-12	Common Stock (125000)	Direct

Footnotes

F1: This option is being awarded by the Board of Directors.